Status:
COMPLETED
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
Lead Sponsor:
Allergan
Conditions:
Presbyopia
Eligibility:
All Genders
40-55 years
Phase:
PHASE2
Brief Summary
A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).
Eligibility Criteria
Inclusion
- Presbyopia in each eye that impacts daily activities.
Exclusion
- Use of any topical ophthalmic medications, including artificial tears
- Contact lens use in either eye within 14 days or planned use during the study
- History of eye surgery
- Diagnosis of any type of glaucoma or ocular hypertension
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT02197806
Start Date
July 1 2014
End Date
November 1 2014
Last Update
December 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Newport Beach, California, United States